Chronic Thromboembolic Pulmonary Hypertension Market 2026: Primary Research + Expert Analysis

Chronic Thromboembolic Pulmonary Hypertension by Type (/> Transthoracic Echocardiogram (TTE), Ventilation-Perfusion (V/Q) Scan, Pulmonary Angiography, Heart Catheterization, Computed Tomography (CT) Pulmonary Angiography, Others), by Application (/> Hospitals, Ambulatory Surgical Centers, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.4 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $1.4 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Loading report content...

Chronic Thromboembolic Pulmonary Hypertension Market 2026: Primary Research + Expert Analysis

Table of Contents

11 items

1. Executive Summary

2. Chronic Thromboembolic Pulmonary Hypertension Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chronic Thromboembolic Pulmonary Hypertension Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chronic Thromboembolic Pulmonary Hypertension Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Transthoracic Echocardiogram (TTE)

6.1.2. Ventilation-Perfusion (V/Q) Scan

6.1.3. Pulmonary Angiography

6.1.4. Heart Catheterization

6.1.5. Computed Tomography (CT) Pulmonary Angiography

6.1.6. Others

6.2. Global Chronic Thromboembolic Pulmonary Hypertension Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Ambulatory Surgical Centers

6.2.3. Others

6.3. Global Chronic Thromboembolic Pulmonary Hypertension Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chronic Thromboembolic Pulmonary Hypertension Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chronic Thromboembolic Pulmonary Hypertension Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Chronic Thromboembolic Pulmonary Hypertension Market Competition by Key Manufacturers

8.1. Global Chronic Thromboembolic Pulmonary Hypertension Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chronic Thromboembolic Pulmonary Hypertension: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bayer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Johnson & Johnson

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Nippon Shinyaku

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GlaxoSmithKline

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sun Pharmaceutical Industries

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Scipharm SaRL

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Promedica International

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Medical Research Network

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Gilead Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Daiichi Sankyo

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chronic Thromboembolic Pulmonary Hypertension Market

Figure 4: Global Chronic Thromboembolic Pulmonary Hypertension Market: Drivers

Figure 5: Global Chronic Thromboembolic Pulmonary Hypertension Market: Challenges

Figure 6: Global Chronic Thromboembolic Pulmonary Hypertension Market: Trends

Figure 7: Global Chronic Thromboembolic Pulmonary Hypertension Market: Opportunity

Figure 8: Global Chronic Thromboembolic Pulmonary Hypertension Market: Restraint

Figure 9: Global Chronic Thromboembolic Pulmonary Hypertension Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Chronic Thromboembolic Pulmonary Hypertension Market Value (USD Million) By Region

Figure 15: Global Chronic Thromboembolic Pulmonary Hypertension Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Chronic Thromboembolic Pulmonary Hypertension Market Value (USD Million) By Region

Figure 23: Global Chronic Thromboembolic Pulmonary Hypertension Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Chronic Thromboembolic Pulmonary Hypertension Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Chronic Thromboembolic Pulmonary Hypertension Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Chronic Thromboembolic Pulmonary Hypertension Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Chronic Thromboembolic Pulmonary Hypertension Market Value (USD Million) By Region

Table 10: Global Chronic Thromboembolic Pulmonary Hypertension Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Chronic Thromboembolic Pulmonary Hypertension Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chronic Thromboembolic Pulmonary Hypertension Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chronic Thromboembolic Pulmonary Hypertension Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bayer Basic Information And Sales Area

Table 31: Bayer. Products Portfolio

Table 32: Johnson & Johnson Basic Information And Sales Area

Table 33: Johnson & Johnson. Products Portfolio

Table 34: Nippon Shinyaku Basic Information And Sales Area

Table 35: Nippon Shinyaku. Products Portfolio

Table 36: GlaxoSmithKline Basic Information And Sales Area

Table 37: GlaxoSmithKline. Products Portfolio

Table 38: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 39: Sun Pharmaceutical Industries. Products Portfolio

Table 40: Scipharm SaRL Basic Information And Sales Area

Table 41: Scipharm SaRL. Products Portfolio

Table 42: Promedica International Basic Information And Sales Area

Table 43: Promedica International. Products Portfolio

Table 44: Medical Research Network Basic Information And Sales Area

Table 45: Medical Research Network. Products Portfolio

Table 46: Gilead Sciences Basic Information And Sales Area

Table 47: Gilead Sciences. Products Portfolio

Table 48: Daiichi Sankyo Basic Information And Sales Area

Table 49: Daiichi Sankyo. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Chronic Thromboembolic Pulmonary Hypertension Market Value (USD Million) By Region

Table 55: Global Chronic Thromboembolic Pulmonary Hypertension Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the projected Compound Annual Growth Rate (CAGR) of the Chronic Thromboembolic Pulmonary Hypertension?

The projected CAGR is approximately 9.2.

2. Which companies are prominent players in the Chronic Thromboembolic Pulmonary Hypertension?

Key companies in the market include Bayer, Johnson & Johnson, Nippon Shinyaku, GlaxoSmithKline, Sun Pharmaceutical Industries, Scipharm SaRL, Promedica International, Medical Research Network, Gilead Sciences, Daiichi Sankyo.

3. What are the main segments of the Chronic Thromboembolic Pulmonary Hypertension?

The market segments include Type, Application.

4. Can you provide details about the market size?

The market size is estimated to be 1.4

5. What are some drivers contributing to market growth?

Increasing Demand for Various Applications to Aid Market Growth.

6. What are the notable trends driving market growth?

Increasing Demand for Various Applications to Aid Market Growth.

7. Are there any restraints impacting market growth?

Increasing Demand for Various Applications to Aid Market Growth.

8. Can you provide examples of recent developments in the market?

Recent developments data is not available.

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4480.00, USD 6720.00, and USD 8960.00 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in 1.4.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "Chronic Thromboembolic Pulmonary Hypertension," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the Chronic Thromboembolic Pulmonary Hypertension report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided with the report for further details.

14. How can I stay updated on further developments or reports in the Chronic Thromboembolic Pulmonary Hypertension?

To stay informed about further developments, trends, and reports in the Chronic Thromboembolic Pulmonary Hypertension, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Table of Contents